{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T14:24:35Z","timestamp":1794320675164,"version":"4.9.0"},"reference-count":64,"publisher":"American Association for Cancer Research (AACR)","issue":"12","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012486","name":"Innovation-Driven Project of Central South University","doi-asserted-by":"crossref","award":["2023CXQD059"],"award-info":[{"award-number":["2023CXQD059"]}],"id":[{"id":"10.13039\/501100012486","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81772800"],"award-info":[{"award-number":["81772800"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82072945"],"award-info":[{"award-number":["82072945"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100019092","name":"Natural Science Foundation for Distinguished Young Scholars of Hunan Province","doi-asserted-by":"crossref","award":["2022JJ10092"],"award-info":[{"award-number":["2022JJ10092"]}],"id":[{"id":"10.13039\/501100019092","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004761","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"crossref","award":["2022JJ30870"],"award-info":[{"award-number":["2022JJ30870"]}],"id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100019081","name":"Science and Technology Program of Hunan Province","doi-asserted-by":"crossref","award":["2022GK4020"],"award-info":[{"award-number":["2022GK4020"]}],"id":[{"id":"10.13039\/501100019081","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Tyrosine kinase inhibitors (TKI) that can suppress the VEGF signaling pathway and angiogenesis have been developed to impede the progression of malignant tumors and have been approved as first-line targeted agents for clear cell renal cell carcinoma (ccRCC). Dysregulation of lipid metabolism is a major driver of TKI resistance in renal cancer. In this study, we showed that the palmitoyl acyltransferase ZDHHC2 is abnormally upregulated in tissues and cell lines resistant to TKIs, such as sunitinib. Upregulation of ZDHHC2 contributed to sunitinib resistance in cells and mice, and ZDHHC2 regulated angiogenesis and cell proliferation in ccRCC. Mechanistically, ZDHHC2 mediated AGK S-palmitoylation to promote translocation of AGK into the plasma membrane and activation of the PI3K\u2013AKT\u2013mTOR signaling pathway in ccRCC, which modulated sunitinib sensitivity. In conclusion, these results identify a ZDHHC2\u2013AGK signaling axis and suggest that ZDHHC2 is a targetable candidate for improving the antitumor efficacy of sunitinib in ccRCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>ZDHHC2 confers sunitinib resistance to clear cell renal cell carcinoma by catalyzing AGK palmitoylation to activate the AKT\u2013mTOR pathway.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-22-3105","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T09:29:58Z","timestamp":1681982998000},"page":"2034-2051","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["ZDHHC2-Mediated AGK Palmitoylation Activates AKT\u2013mTOR Signaling to Reduce Sunitinib Sensitivity in Renal Cell Carcinoma"],"prefix":"10.1158","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8339-7116","authenticated-orcid":false,"given":"Yan","family":"Sun","sequence":"first","affiliation":[{"name":"1Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China."},{"name":"2Department of pancreatic surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1614-6576","authenticated-orcid":false,"given":"Liang","family":"Zhu","sequence":"additional","affiliation":[{"name":"1Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China."},{"name":"3Uro-Oncology Institute of Central South University, Changsha, Hunan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5780-3902","authenticated-orcid":false,"given":"Pian","family":"Liu","sequence":"additional","affiliation":[{"name":"4Cancer center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4918-5194","authenticated-orcid":false,"given":"Huan","family":"Zhang","sequence":"additional","affiliation":[{"name":"2Department of pancreatic surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0882-5296","authenticated-orcid":false,"given":"Feng","family":"Guo","sequence":"additional","affiliation":[{"name":"2Department of pancreatic surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6461-6005","authenticated-orcid":false,"given":"Xin","family":"Jin","sequence":"additional","affiliation":[{"name":"1Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China."},{"name":"3Uro-Oncology Institute of Central South University, Changsha, Hunan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"2025112417530550500_bib1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nrc3844","article-title":"VHL, the story of a tumor suppressor gene","volume":"15","author":"Gossage","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"2025112417530550500_bib2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1126\/science.aap8411","article-title":"VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma","volume":"361","author":"Zhang","year":"2018","journal-title":"Science"},{"key":"2025112417530550500_bib3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jtho.2020.10.006","article-title":"Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC","volume":"16","author":"Le","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025112417530550500_bib4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ctrv.2018.07.009","article-title":"Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma","volume":"70","author":"Atkins","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"2025112417530550500_bib5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12943-018-0801-5","article-title":"Advances in studies of tyrosine kinase inhibitors and their acquired resistance","volume":"17","author":"Jiao","year":"2018","journal-title":"Mol Cancer"},{"key":"2025112417530550500_bib6","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.molcel.2022.01.029","article-title":"Fumarate inhibits PTEN to promote tumorigenesis and therapeutic resistance of type2 papillary renal cell carcinoma","volume":"82","author":"Ge","year":"2022","journal-title":"Mol Cell"},{"key":"2025112417530550500_bib7","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ng0497-356","article-title":"Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers","volume":"15","author":"Steck","year":"1997","journal-title":"Nat Genet"},{"key":"2025112417530550500_bib8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12032-021-01462-5","article-title":"Combating TKI resistance in CML by inhibiting the PI3K\u2013Akt\u2013mTOR pathway in combination with TKIs: a review","volume":"38","author":"Singh","year":"2021","journal-title":"Med Oncol"},{"key":"2025112417530550500_bib9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fonc.2014.00064","article-title":"Targeting PI3K\u2013Akt\u2013mTOR signaling in cancer","volume":"4","author":"Porta","year":"2014","journal-title":"Front Oncol"},{"key":"2025112417530550500_bib10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1186\/s13046-019-1486-3","article-title":"Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties","volume":"38","author":"Si","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"2025112417530550500_bib11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41419-017-0120-6","article-title":"Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN\/AKT signaling pathway","volume":"9","author":"Wang","year":"2018","journal-title":"Cell Death Dis"},{"key":"2025112417530550500_bib12","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.21873\/anticanres.14149","article-title":"PTEN is involved in sunitinib and sorafenib resistance in renal cell carcinoma","volume":"40","author":"Sekino","year":"2020","journal-title":"Anticancer Res"},{"key":"2025112417530550500_bib13","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1158\/1535-7163.MCT-11-0907","article-title":"Modulation of Akt\u2013mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells","volume":"11","author":"Makhov","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"2025112417530550500_bib14","doi-asserted-by":"crossref","first-page":"e2100881","DOI":"10.1002\/advs.202100881","article-title":"RRM2 regulates sensitivity to sunitinib and PD-1 blockade in renal cancer by stabilizing ANXA1 and activating the AKT pathway","volume":"8","author":"Xiong","year":"2021","journal-title":"Adv Sci"},{"key":"2025112417530550500_bib15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41420-022-00933-6","article-title":"Single-cell RNA sequencing analysis reveals MYH9 promotes renal cell carcinoma development and sunitinib resistance via AKT signaling pathway","volume":"8","author":"Xu","year":"2022","journal-title":"Cell Death Discov"},{"key":"2025112417530550500_bib16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/iub.1942","article-title":"NT5E inhibition suppresses the growth of sunitinib-resistant cells and EMT course and AKT\/GSK-3beta signaling pathway in renal cell cancer","volume":"71","author":"Peng","year":"2019","journal-title":"IUBMB Life"},{"key":"2025112417530550500_bib17","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.7150\/thno.69826","article-title":"AGK regulates the progression to NASH by affecting mitochondria complex I function","volume":"12","author":"Ding","year":"2022","journal-title":"Theranostics"},{"key":"2025112417530550500_bib18","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1083\/jcb.200407123","article-title":"A novel acylglycerol kinase that produces lysophosphatidic acid modulates cross-talk with EGFR in prostate cancer cells","volume":"169","author":"Bektas","year":"2005","journal-title":"J Cell Biol"},{"key":"2025112417530550500_bib19","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.cmet.2019.05.016","article-title":"Acylglycerol kinase maintains metabolic state and immune responses of CD8(+) T cells","volume":"30","author":"Hu","year":"2019","journal-title":"Cell Metab"},{"key":"2025112417530550500_bib20","doi-asserted-by":"crossref","first-page":"12057","DOI":"10.18632\/oncotarget.2666","article-title":"AGK enhances angiogenesis and inhibits apoptosis via activation of the NF-\u03baB signaling pathway in hepatocellular carcinoma","volume":"5","author":"Cui","year":"2014","journal-title":"Oncotarget"},{"key":"2025112417530550500_bib21","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1245\/s10434-015-4597-x","article-title":"Receptor tyrosine kinase expression predicts response to sunitinib in breast cancer","volume":"22","author":"Spanheimer","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"2025112417530550500_bib22","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1530\/EC-19-0192","article-title":"EGF and IGF1 affect sunitinib activity in BP-NEN: new putative targets beyond VEGFR?","volume":"8","author":"Bresciani","year":"2019","journal-title":"Endocr Connect"},{"key":"2025112417530550500_bib23","doi-asserted-by":"crossref","first-page":"e1637","DOI":"10.1038\/cddis.2015.2","article-title":"p21-activated kinase 1 determines stem-like phenotype and sunitinib resistance via NF-\u03baB\/IL6 activation in renal cell carcinoma","volume":"6","author":"Zhu","year":"2015","journal-title":"Cell Death Dis"},{"key":"2025112417530550500_bib24","doi-asserted-by":"crossref","first-page":"15427","DOI":"10.1074\/jbc.RA120.013815","article-title":"The palmitoyl acyltransferases ZDHHC5 and ZDHHC8 are uniquely present in DRG axons and control retrograde signaling via the Gp130\/JAK\/STAT3 pathway","volume":"295","author":"Collura","year":"2020","journal-title":"J Biol Chem"},{"key":"2025112417530550500_bib25","doi-asserted-by":"crossref","first-page":"e46666","DOI":"10.15252\/embr.201846666","article-title":"Protein palmitoylation and cancer","volume":"19","author":"Ko","year":"2018","journal-title":"EMBO Rep"},{"key":"2025112417530550500_bib26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1083\/jcb.200206120","article-title":"The yeast DHHC cysteine-rich domain protein Akr1p is a palmitoyl transferase","volume":"159","author":"Roth","year":"2002","journal-title":"J Cell Biol"},{"key":"2025112417530550500_bib27","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nrm2084","article-title":"Palmitoylation: policing protein stability and traffic","volume":"8","author":"Linder","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2025112417530550500_bib28","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/bju.15625","article-title":"Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the immediate surgery or surgery after sunitinib malate in treating patients with metastatic kidney cancer (SURTIME) trial","volume":"130","author":"Abu-Ghanem","year":"2022","journal-title":"BJU Int"},{"key":"2025112417530550500_bib29","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13046-022-02253-0","article-title":"A novel FBW7\/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression","volume":"41","author":"Liu","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"2025112417530550500_bib30","first-page":"360","article-title":"Ultrastructural studies of peripheral nerves in lepromatous leprosy patients","volume":"60","author":"Kumar","year":"1988","journal-title":"Indian J Lepr"},{"key":"2025112417530550500_bib31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41419-023-05577-7","article-title":"TRIM15 forms a regulatory loop with the AKT\/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs","volume":"14","author":"Yang","year":"2023","journal-title":"Cell Death Dis"},{"key":"2025112417530550500_bib32","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.7150\/ijbs.68980","article-title":"OTUD1 stabilizes PTEN to inhibit the PI3K\/AKT and TNF-alpha\/NF-kappaB signaling pathways and sensitize ccRCC to TKIs","volume":"18","author":"Liu","year":"2022","journal-title":"Int J Biol Sci"},{"key":"2025112417530550500_bib33","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/s41419-021-04260-z","article-title":"The FOXM1\/RNF26\/p57 axis regulates the cell cycle to promote the aggressiveness of bladder cancer","volume":"12","author":"Yi","year":"2021","journal-title":"Cell Death Dis"},{"key":"2025112417530550500_bib34","doi-asserted-by":"crossref","first-page":"5872","DOI":"10.1038\/s41467-021-26180-4","article-title":"DHHC9-mediated GLUT1 S-palmitoylation promotes glioblastoma glycolysis and tumorigenesis","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat Commun"},{"key":"2025112417530550500_bib35","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1194\/jlr.R600007-JLR200","article-title":"Protein palmitoylation by a family of DHHC protein S-acyltransferases","volume":"47","author":"Mitchell","year":"2006","journal-title":"J Lipid Res"},{"key":"2025112417530550500_bib36","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrn2788","article-title":"Protein palmitoylation in neuronal development and synaptic plasticity","volume":"11","author":"Fukata","year":"2010","journal-title":"Nat Rev Neurosci"},{"key":"2025112417530550500_bib37","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fnmol.2011.00051","article-title":"PI3K\u2013AKT\u2013mTOR pathway in angiogenesis","volume":"4","author":"Karar","year":"2011","journal-title":"Front Mol Neurosci"},{"key":"2025112417530550500_bib38","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"2025112417530550500_bib39","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1470-2045(11)70124-3","article-title":"Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomized phase II trial","volume":"12","author":"Negrier","year":"2011","journal-title":"Lancet Oncol"},{"key":"2025112417530550500_bib40","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/annonc\/mdt578","article-title":"Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies","volume":"25","author":"Voss","year":"2014","journal-title":"Ann Oncol"},{"key":"2025112417530550500_bib41","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.eururo.2010.09.008","article-title":"Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma","volume":"58","author":"Di Lorenzo","year":"2010","journal-title":"Eur Urol"},{"key":"2025112417530550500_bib42","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00432-012-1162-x","article-title":"Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines","volume":"138","author":"Martin","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025112417530550500_bib43","first-page":"00248","article-title":"First-line lenvatinib plus pembrolizumab or everolimus versus sunitinib for advanced renal cell carcinoma: a United States-based cost-effectiveness analysis","volume":"S1558\u20137673","author":"Zhu","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"2025112417530550500_bib44","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/CAD.0000000000000335","article-title":"First-line therapy for treatment-naive patients with advanced\/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials","volume":"27","author":"Takyar","year":"2016","journal-title":"Anticancer Drugs"},{"key":"2025112417530550500_bib45","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13045-019-0840-4","article-title":"Acylglycerol kinase promotes tumor growth and metastasis via activating the PI3K\/AKT\/GSK3beta signaling pathway in renal cell carcinoma","volume":"13","author":"Zhu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2025112417530550500_bib46","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1182\/blood.2019003851","article-title":"The role of AGK in thrombocytopoiesis and possible therapeutic strategies","volume":"136","author":"Jiang","year":"2020","journal-title":"Blood"},{"key":"2025112417530550500_bib47","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41374-019-0188-y","article-title":"Epithelial\u2013mesenchymal transition as a mechanism of resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma","volume":"99","author":"Hwang","year":"2019","journal-title":"Lab Invest"},{"key":"2025112417530550500_bib48","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.3390\/cancers13235981","article-title":"Molecular mechanisms of resistance to immunotherapy and antiangiogenic treatments in clear cell renal cell carcinoma","volume":"13","author":"Ballesteros","year":"2021","journal-title":"Cancers"},{"key":"2025112417530550500_bib49","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/nchembio.2119","article-title":"ZDHHC7-mediated S-palmitoylation of scribble regulates cell polarity","volume":"12","author":"Chen","year":"2016","journal-title":"Nat Chem Biol"},{"key":"2025112417530550500_bib50","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41551-019-0375-6","article-title":"Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumors","volume":"3","author":"Yao","year":"2019","journal-title":"Nat Biomed Eng"},{"key":"2025112417530550500_bib51","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.molcel.2016.04.003","article-title":"Inhibition of DHHC20-mediated EGFR palmitoylation creates a dependence on EGFR signaling","volume":"62","author":"Runkle","year":"2016","journal-title":"Mol Cell"},{"key":"2025112417530550500_bib52","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.lungcan.2015.01.023","article-title":"Multiple resistant factors in lung cancer with primary resistance to EGFR-TK inhibitors confer poor survival","volume":"88","author":"Kim","year":"2015","journal-title":"Lung Cancer"},{"key":"2025112417530550500_bib53","doi-asserted-by":"crossref","first-page":"e103305","DOI":"10.1371\/journal.pone.0103305","article-title":"Alteration in Mir-21\/PTEN expression modulates gefitinib resistance in non\u2013small cell lung cancer","volume":"9","author":"Shen","year":"2014","journal-title":"PLoS One"},{"key":"2025112417530550500_bib54","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/bjc.2017.292","article-title":"Activation of an AKT\/FOXM1\/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer","volume":"117","author":"Li","year":"2017","journal-title":"Br J Cancer"},{"key":"2025112417530550500_bib55","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2799-2","article-title":"A STAT3 palmitoylation cycle promotes TH17 differentiation and colitis","volume":"586","author":"Zhang","year":"2020","journal-title":"Nature"},{"key":"2025112417530550500_bib56","doi-asserted-by":"crossref","first-page":"659861","DOI":"10.3389\/fmolb.2021.659861","article-title":"Palmitoylation as a key regulator of Ras localization and function","volume":"8","author":"Busquets-Hernandez","year":"2021","journal-title":"Front Mol Biosci"},{"key":"2025112417530550500_bib57","doi-asserted-by":"crossref","first-page":"e8313","DOI":"10.15252\/emmm.201708313","article-title":"Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non\u2013small cell lung cancer","volume":"10","author":"Ali","year":"2018","journal-title":"EMBO Mol Med"},{"key":"2025112417530550500_bib58","doi-asserted-by":"crossref","first-page":"562868","DOI":"10.3389\/fgene.2020.562868","article-title":"Epigenetic alterations in renal cell cancer with TKIs resistance: from mechanisms to clinical applications","volume":"11","author":"Li","year":"2020","journal-title":"Front Genet"},{"key":"2025112417530550500_bib59","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/1535-7163.MCT-17-1299","article-title":"Resistance to systemic therapies in clear cell renal cell carcinoma: mechanisms and management strategies","volume":"17","author":"Makhov","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"2025112417530550500_bib60","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.drup.2014.10.003","article-title":"Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms","volume":"17","author":"van der Mijn","year":"2014","journal-title":"Drug Resist Updat"},{"key":"2025112417530550500_bib61","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ejca.2011.11.027","article-title":"Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study","volume":"48","author":"Calvo","year":"2012","journal-title":"Eur J Cancer"},{"key":"2025112417530550500_bib62","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.isci.2019.10.047","article-title":"HIF-mediated suppression of DEPTOR confers resistance to mTOR kinase inhibition in renal cancer","volume":"21","author":"Doan","year":"2019","journal-title":"iScience"},{"key":"2025112417530550500_bib63","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1038\/s41401-022-00862-1","article-title":"PTEN loss confers sensitivity to rapalogs in clear cell renal cell carcinoma","volume":"43","author":"Liu","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"2025112417530550500_bib64","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/cam4.3578","article-title":"Functional and genomic characterization of patient-derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma","volume":"10","author":"Sakamoto","year":"2021","journal-title":"Cancer Med"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-22-3105\/3324931\/can-22-3105.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-22-3105\/3338473\/can-22-3105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/83\/12\/2034\/3339390\/2034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/83\/12\/2034\/3339390\/2034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T22:53:23Z","timestamp":1764024803000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/83\/12\/2034\/727175\/ZDHHC2-Mediated-AGK-Palmitoylation-Activates-AKT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":64,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,4,20]]},"published-print":{"date-parts":[[2023,6,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-22-3105","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6678641.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6678641.v2","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.23522258.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6678641.v3","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.23289563","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6678641","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.23522258","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.23289563.v1","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.23522258.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27027629.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.23289563","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30700051","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.23522258","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.23289563.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27027629","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]}}}